11 citations
,
August 2017 in “Supportive care in cancer” This study highlights the significant impact of eyebrow and eyelash loss during chemotherapy on women's quality of life, noting both emotional and physical challenges.
May 2019 in “Journal of clinical oncology” This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
This review discusses various strategies to mitigate taxane-induced alopecia in cancer treatment, highlighting the potential of low-intensity ultrasound to reverse hair follicle damage by disrupting taxane-stabilized microtubules.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
25 citations
,
March 2018 in “Journal of oncology practice” This study found that scalp cooling effectively reduces chemotherapy-induced hair loss, especially with taxane-based regimens, and recent U.S. trials support its safety, despite logistical and insurance challenges.
